Literature DB >> 22713862

Luteinizing hormone correlates with adrenal function in postmenopausal women.

Aditi R Saxena1, Ellen W Seely.   

Abstract

OBJECTIVE: In postmenopausal women, a relationship between luteinizing hormone (LH) and cortisol levels has been suggested. Furthermore, LH receptors in the adrenal gland have been shown to mediate adrenocorticotropic hormone-independent Cushing syndrome. In contrast, follicle-stimulating hormone (FSH) receptors have not been found in the adrenal gland. Our objective was to explore the relationship of LH with adrenal function in postmenopausal women, as assessed by 24-hour urinary free cortisol (UFC) and aldosterone excretion rate (AER).
METHODS: Participants were studied at a single time point in the fasting state in the Clinical Research Center of Brigham and Women's Hospital. We studied 36 postmenopausal women in sodium balance to control for variation in endogenous levels of plasma renin activity and angiotensin II. Serum cortisol, aldosterone, LH, and FSH levels were measured, as were 24-hour UFC and AER. Correlations were performed by calculation of Pearson's correlation coefficient.
RESULTS: Serum LH correlated significantly with log-transformed UFC (r = 0.43, P = 0.01) and inversely with log AER (r = -0.50, P = 0.002). We found no correlation of serum LH with serum cortisol or aldosterone, nor did we find correlation of FSH with these parameters.
CONCLUSIONS: In postmenopausal women, serum LH levels correlate significantly with UFC (positively) and AER (negatively). LH stimulation may induce subtle shifts in adrenal function toward cortisol secretion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22713862      PMCID: PMC3459175          DOI: 10.1097/gme.0b013e31825540c4

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  23 in total

1.  Leuprolide acetate therapy in luteinizing hormone--dependent Cushing's syndrome.

Authors:  A Lacroix; P Hamet; J M Boutin
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

2.  Leuprolide acetate therapy in LH-dependent Cushing's syndrome: in vivo and in vitro observations.

Authors:  S A Bovenberg; G F F M Pieters; L J Hofland; A R M M Hermus
Journal:  Neth J Med       Date:  2004-12       Impact factor: 1.422

3.  Elevated expression of luteinizing hormone receptor in aldosterone-producing adenomas.

Authors:  Karla Saner-Amigh; Bobbie A Mayhew; Franco Mantero; Francesca Schiavi; Perrin C White; Chalama V Rao; William E Rainey
Journal:  J Clin Endocrinol Metab       Date:  2005-12-06       Impact factor: 5.958

4.  The adrenal gland may be a target of LH action in postmenopausal women.

Authors:  Maria Alevizaki; Katerina Saltiki; Emily Mantzou; Eleni Anastasiou; Ilpo Huhtaniemi
Journal:  Eur J Endocrinol       Date:  2006-06       Impact factor: 6.664

5.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

Review 6.  The ontogenesis of the steroidogenic tissues.

Authors:  K Morohashi
Journal:  Genes Cells       Date:  1997-02       Impact factor: 1.891

7.  Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension.

Authors:  W R Litchfield; S C Hunt; X Jeunemaitre; N D Fisher; P N Hopkins; R R Williams; P Corvol; G H Williams
Journal:  Hypertension       Date:  1998-02       Impact factor: 10.190

8.  Ovarian steroidogenesis and serum androgen levels in patients with premature ovarian failure.

Authors:  Anne Bachelot; Géri Meduri; Nathalie Massin; Micheline Misrahi; Frédérique Kuttenn; Philippe Touraine
Journal:  J Clin Endocrinol Metab       Date:  2005-01-25       Impact factor: 5.958

9.  A case of primary aldosteronism in pregnancy: do LH and GNRH receptors have a potential role in regulating aldosterone secretion?

Authors:  N M Albiger; P Sartorato; B Mariniello; M Iacobone; I Finco; A Fassina; F Mantero
Journal:  Eur J Endocrinol       Date:  2011-03       Impact factor: 6.664

Review 10.  Fetal and maternal adrenals in human pregnancy.

Authors:  William E Rainey; Khurram S Rehman; Bruce R Carr
Journal:  Obstet Gynecol Clin North Am       Date:  2004-12       Impact factor: 2.844

View more
  5 in total

1.  Ovarian adrenal interactions during the menopausal transition.

Authors:  B L Lasley; S L Crawford; D S McConnell
Journal:  Minerva Ginecol       Date:  2013-12

2.  Ovarian and adrenal androgens and their link to high human chorionic gonadotropin levels: a prospective controlled study.

Authors:  René Rodríguez-Gutiérrez; Jesús Zacarías Villarreal-Pérez; Felipe Arturo Morales-Martinez; René Rodríguez-Guajardo; Gloria González-Saldivar; Leonardo G Mancillas-Adame; Neri Alejandro Alvarez-Villalobos; Fernando Javier Lavalle-Gonzalez; José Gerardo González-González
Journal:  Int J Endocrinol       Date:  2014-11-23       Impact factor: 3.257

3.  Associations of blood lead levels with reproductive hormone levels in men and postmenopausal women: Results from the SPECT-China Study.

Authors:  Chi Chen; Ningjian Wang; Hualing Zhai; Xiaomin Nie; Honglin Sun; Bing Han; Qin Li; Yi Chen; Jing Cheng; Fangzhen Xia; Li Zhao; Yanjun Zheng; Zhoujun Shen; Yingli Lu
Journal:  Sci Rep       Date:  2016-11-29       Impact factor: 4.379

4.  Primary aldosteronism in Klinefelter's syndrome: two cases.

Authors:  Yasufumi Seki; Satoshi Morimoto; Naohiro Yoshida; Kanako Bokuda; Nobukazu Sasaki; Midori Yatabe; Junichi Yatabe; Daisuke Watanabe; Satoru Morita; Keisuke Hata; Tomoko Yamamoto; Yoji Nagashima; Atsuhiro Ichihara
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2019-12-16

5.  Adrenocortical production is associated with higher levels of luteinizing hormone in nonobese women with polycystic ovary syndrome.

Authors:  Luciana Tock; Gláucia Carneiro; Andrea Z Pereira; Sérgio Tufik; Maria Teresa Zanella
Journal:  Int J Endocrinol       Date:  2014-05-07       Impact factor: 3.257

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.